EA201892119A1 - Лекарственный препарат, полученный путем комбинирования агониста fxr и arb - Google Patents

Лекарственный препарат, полученный путем комбинирования агониста fxr и arb

Info

Publication number
EA201892119A1
EA201892119A1 EA201892119A EA201892119A EA201892119A1 EA 201892119 A1 EA201892119 A1 EA 201892119A1 EA 201892119 A EA201892119 A EA 201892119A EA 201892119 A EA201892119 A EA 201892119A EA 201892119 A1 EA201892119 A1 EA 201892119A1
Authority
EA
Eurasian Patent Office
Prior art keywords
arb
fxr
agonist
drugs
combining
Prior art date
Application number
EA201892119A
Other languages
English (en)
Other versions
EA037330B1 (ru
Inventor
Тадаси Намисаки
Хитоси Йосидзи
Original Assignee
Интерсепт Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Интерсепт Фармасьютикалз, Инк. filed Critical Интерсепт Фармасьютикалз, Инк.
Publication of EA201892119A1 publication Critical patent/EA201892119A1/ru
Publication of EA037330B1 publication Critical patent/EA037330B1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

В настоящем изобретении представлено терапевтическое средство для NASH, содержащее агонист FXR, предпочтительно обетихолевую кислоту или ее фармацевтически приемлемую соль; и ARB или его фармацевтически приемлемую соль.
EA201892119A 2016-03-28 2017-03-27 Лекарственный препарат, полученный путем комбинирования агониста fxr и arb EA037330B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016064475 2016-03-28
PCT/JP2017/012448 WO2017170434A1 (ja) 2016-03-28 2017-03-27 Fxrアゴニストとarbの組み合わせ医薬

Publications (2)

Publication Number Publication Date
EA201892119A1 true EA201892119A1 (ru) 2019-02-28
EA037330B1 EA037330B1 (ru) 2021-03-12

Family

ID=59965591

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201892119A EA037330B1 (ru) 2016-03-28 2017-03-27 Лекарственный препарат, полученный путем комбинирования агониста fxr и arb

Country Status (17)

Country Link
US (1) US11419878B2 (ru)
EP (1) EP3437659B1 (ru)
JP (1) JPWO2017170434A1 (ru)
KR (1) KR20180124123A (ru)
CN (1) CN109152840A (ru)
AU (1) AU2017241559A1 (ru)
BR (1) BR112018069789A2 (ru)
CA (1) CA3019496A1 (ru)
CL (1) CL2018002727A1 (ru)
EA (1) EA037330B1 (ru)
IL (1) IL262057A (ru)
MX (1) MX2018011813A (ru)
PH (1) PH12018502109A1 (ru)
SG (1) SG11201808607SA (ru)
TW (1) TW201733582A (ru)
UA (1) UA124499C2 (ru)
WO (1) WO2017170434A1 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022508402A (ja) * 2018-08-30 2022-01-19 ターンズ・ファーマシューティカルズ・インコーポレイテッド 肝障害の治療
MX2021005316A (es) * 2018-11-08 2021-09-10 Intercept Pharmaceuticals Inc Métodos de uso del ácido obeticólico.
DE102019108825A1 (de) * 2019-04-04 2020-10-08 Eberhard Karls Universität Tübingen Medizinische Fakultät Verbindungen und Verfahren zur Behandlung von Erkrankungen der Leber
KR20210020788A (ko) 2019-08-14 2021-02-24 주식회사 바이오톡스텍 하이드로퀴논 유도체, 및 오베티콜릭산을 포함하는 비알콜성 지방간염의 예방 또는 치료용 약학조성물
EP4054567A4 (en) * 2019-11-08 2024-01-10 Terns Pharmaceuticals Inc TREATMENT OF LIVER DISEASES
WO2021133948A1 (en) * 2019-12-23 2021-07-01 Axcella Health Inc. Compositions and methods for the treatment of liver diseases and disorders
BR112022022952A2 (pt) * 2020-05-13 2023-01-10 Terns Pharmaceuticals Inc Tratamento combinado de distúrbios hepáticos
WO2022046779A1 (en) 2020-08-25 2022-03-03 Eli Lilly And Company Polymorphs of an ssao inhibitor
KR20230043773A (ko) 2021-09-24 2023-03-31 (주)샤페론 염증복합체 억제제를 유효성분으로 함유하는, 비알코올성 지방간염, 간 섬유화의 예방, 개선 또는 치료용 약학적 조성물
KR20230052237A (ko) 2021-10-12 2023-04-19 (주)샤페론 타우로데옥시콜산 신규 제제
WO2023140350A1 (ja) * 2022-01-21 2023-07-27 国立大学法人 長崎大学 臓器の線維化抑制用医薬組成物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138390B2 (en) 2001-03-12 2006-11-21 Intercept Pharmaceuticals Steroids as agonists for FXR
JP5094384B2 (ja) 2004-03-12 2012-12-12 インターセプト ファーマシューティカルズ, インコーポレイテッド Fxrリガンドを使用する線維症の処置
JP5222846B2 (ja) 2006-06-27 2013-06-26 インターセプト ファーマシューティカルズ, インコーポレイテッド Fxr媒介疾患または状態の予防または治療のためのfxrリガンドとしての胆汁酸誘導体
TW200906823A (en) 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
EP2289883A1 (en) 2009-08-19 2011-03-02 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
US9238673B2 (en) 2012-06-19 2016-01-19 Intercept Pharmaceuticals, Inc. Preparation and uses of obeticholic acid
CN105592846A (zh) * 2013-03-15 2016-05-18 持田制药株式会社 用于治疗非酒精性脂肪性肝炎的组合物和方法
MX2015011466A (es) * 2013-03-15 2016-01-22 Boehringer Ingelheim Int Uso de linagliptina en terapia antidiabetica cardio-y renoprotectora.
MX2015017035A (es) * 2013-06-13 2016-04-25 Fast Forward Pharmaceuticals B V Inhibidor de la señalizacion de cd40 y un compuesto adicional, en donde el compuesto adicional es un acido labil, un derivado de acido labil, un agonista del receptor tgr5, un agonista del fxr o una combinacion de los mismos, para el tratamiento de inflamacion cronica, y la prevencion de cancer gastrointestinal o fibrosis.
EP3023098B1 (en) * 2013-07-18 2020-06-24 Mochida Pharmaceutical Co., Ltd. Self-emulsifying composition of omega-3 fatty acid
CN105175473B (zh) * 2015-08-19 2018-12-21 丽珠医药集团股份有限公司 一种奥贝胆酸晶型i及其制备方法、药物组合物和用途

Also Published As

Publication number Publication date
UA124499C2 (uk) 2021-09-29
MX2018011813A (es) 2019-01-24
KR20180124123A (ko) 2018-11-20
WO2017170434A1 (ja) 2017-10-05
EP3437659A1 (en) 2019-02-06
TW201733582A (zh) 2017-10-01
EA037330B1 (ru) 2021-03-12
CA3019496A1 (en) 2017-10-05
BR112018069789A2 (pt) 2019-01-29
SG11201808607SA (en) 2018-11-29
IL262057A (en) 2018-11-29
US20190247404A1 (en) 2019-08-15
EP3437659B1 (en) 2023-03-01
JPWO2017170434A1 (ja) 2019-01-31
EP3437659A4 (en) 2019-12-11
CL2018002727A1 (es) 2018-12-07
CN109152840A (zh) 2019-01-04
AU2017241559A1 (en) 2018-11-01
US11419878B2 (en) 2022-08-23
PH12018502109A1 (en) 2019-09-23

Similar Documents

Publication Publication Date Title
EA201892119A1 (ru) Лекарственный препарат, полученный путем комбинирования агониста fxr и arb
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
EA201790528A1 (ru) Дигидропирролопиридиновые ингибиторы ror-гамма
EA201791256A1 (ru) Производные хиназолина, применяемые для лечения вич
EA201790407A1 (ru) Зонды для визуализации белка хантингтина
EA201692436A1 (ru) Медицинское применение
EA201591363A1 (ru) Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn
CY1124251T1 (el) Παραγωγα καρβοξαμιδιου
EA201691600A1 (ru) Дигидропиридиноновые ингибиторы mgat2 для применения в лечении метаболических нарушений
EA201891342A1 (ru) Изоиндольные соединения
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
EA201791227A1 (ru) РЕЖИМ ДОЗИРОВАНИЯ АНТАГОНИСТОВ MAdCAM
TN2019000033A1 (fr) Agents thérapeutiques pour maladies neurodégénératives
EA201790432A1 (ru) Зонды для визуализации белка хантингтина
EA201790400A1 (ru) Зонды для визуализации белка хантингтина
EA201990765A1 (ru) Азаиндазольные соединения для применения при повреждениях сухожилий и/или связок
EA201692298A1 (ru) Производные карбоксамидов
EA201791992A1 (ru) Ингибиторы грелин-o-ацилтрансферазы
EA201792000A1 (ru) Ингибиторы грелин-o-ацилтрансферазы
EA201491517A1 (ru) N-этил-n-фенил-1,2-дигидро-4,5-дигидрокси-1-метил-2-оксо-3-хинолинкарбоксамид, его получение и применения
EA201591717A1 (ru) Твердые формы гидрохлорида вемурафениба
EA201990766A1 (ru) Индазольные соединения для применения при повреждениях сухожилий и/или связок
EA201691796A1 (ru) П-замещенные асимметричные мочевины и их применение в медицине
EA201691231A1 (ru) Фармацевтические лекарственные формы
EA201501130A1 (ru) Офтальмологическая фармацевтическая композиция